Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for GVHD Prevention in AlloHCT
NCT03699631Phase 2Completed
- Sponsor
- Medical College of Wisconsin
- Start
- Nov 2018
- Primary completion
- Mar 2022
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tocilizumab in graft-versus-host disease (GVHD), sponsored by Medical College of Wisconsin. Primary endpoint: GVHD-free/relapse-free survival at Day 365. Started Nov 2018; status: completed.
02
Drugs
tocilizumab
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT03699631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03699631.